PE-22-28 vs Bronchogen
Side-by-side comparison of key properties, dosing, and research.
Cognitive Enhancement
PE-22-28Anti-Aging & Longevity
Bronchogen- Summary
- PE-22-28 is a synthetic analog of spadin derived from sortilin, designed to block TREK-1 potassium channels with rapid-onset antidepressant and neurogenic effects. It shows fast-acting depression relief (within 24 hours) and promotes hippocampal neurogenesis.
- Bronchogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Leu) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is a tissue-specific bioregulator designed for the bronchi and lungs, promoting normalization of bronchial epithelial cell function. Research suggests benefits for respiratory health, protection against pulmonary aging, and support for bronchopulmonary conditions.
- Half-Life
- Relatively short; CNS effects may persist due to neurogenic mechanisms
- Short (minutes to hours); bioregulator effects are gene-mediated and longer lasting
- Admin Route
- SubQ, Intranasal
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 200–400 mcg
- 10 mg per day
- Frequency
- Once daily
- Daily for 10–30 days
- Key Benefits
- Rapid-onset antidepressant effects (within 24 hours)
- Promotes hippocampal neurogenesis
- Improves cognitive performance and memory
- Reduces anxiety and depressive behavior
- Novel mechanism — does not act on serotonin/dopamine/GABA receptors directly
- May help treatment-resistant depression
- Neuroprotective effects
- Tissue-specific support for bronchial and lung health
- Promotes normalization of bronchial epithelial cell function
- Potential benefits in chronic bronchitis and COPD support
- Anti-aging effects on pulmonary tissue
- May reduce frequency of respiratory infections
- Supports lung function preservation with aging
- Compatible with other Khavinson bioregulator peptides
- Side Effects
- Generally well tolerated in animal models
- Limited human data available
- Possible mild headache or transient mood changes at initiation
- Injection site reactions (SC)
- Generally well tolerated in research studies
- Mild local reactions at injection site (if injected)
- No significant systemic side effects reported at standard doses
- Stacks With
- —
- —